hotspot -WSS

hotspot

author：Wikipedia 2025-09-30 01:01:47 - browse：737

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Medicare Advantage proposed rates disappoint insurers

WSS

The dental labor crisis is a moment of opportunity

Former New York Mayor de Blasio and wife announce separation, but not divorce

What we’ve learned from the Aduhelm mess

What should King Charles tell the public about his cancer?

Man pleads guilty to raping Ohio girl who ended up traveling across state lines for abortion

Industry veterans launch new biotech VC with $310M

hotspot

hotspot

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Condition critical? Britain's beloved but battered National Health Service turns 75

Trump demands the U.S. pay no more for drugs than other countries … again

Myanmar's Supreme Court hears arguments in 2 appeals by ousted leader Aung San Suu Kyi

After affirmative action ruling, medical educators look to 'holistic review'

A bus careens into a gulch in southern Mexico, leaving 27 people dead

Trump demands the U.S. pay no more for drugs than other countries … again

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

In age of alternative facts, a scholarly course on calling out crap

What we’ve learned from the Aduhelm mess

focus

Myanmar's Supreme Court hears arguments in 2 appeals by ousted leader Aung San Suu Kyi

Why did Pfizer dish out millions for a Super Bowl ad?

What we’ve learned from the Aduhelm mess

Man pleads guilty to raping Ohio girl who ended up traveling across state lines for abortion

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

hotspot

Wikipedia

explore

Wikipedia